• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.

作者信息

Blackmon Jonathan T, Dhawan Ratika, Viator Toni M, Terry Nina L, Conry Robert M

机构信息

Covenant College, Lookout Mountain, Georgia.

Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

JAAD Case Rep. 2017 Apr 14;3(3):185-189. doi: 10.1016/j.jdcr.2017.02.003. eCollection 2017 May.

DOI:10.1016/j.jdcr.2017.02.003
PMID:28443305
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5394182/
Abstract
摘要

相似文献

1
Talimogene laherparepvec for regionally advanced Merkel cell carcinoma: A report of 2 cases.瘤内注射重组人5型腺病毒治疗局部晚期默克尔细胞癌：2例报告
JAAD Case Rep. 2017 Apr 14;3(3):185-189. doi: 10.1016/j.jdcr.2017.02.003. eCollection 2017 May.
2
Talimogene laherparepvec induces durable response of regionally advanced Merkel cell carcinoma in 4 consecutive patients.Talimogene laherparepvec在连续4例患者中诱导了局部晚期默克尔细胞癌的持久缓解。
JAAD Case Rep. 2019 Aug 29;5(9):782-786. doi: 10.1016/j.jdcr.2019.06.034. eCollection 2019 Sep.
3
Complete clinical response to intralesional talimogene laherparepvec injection in a patient with recurrent, regionally advanced Merkel cell carcinoma.病灶内注射talimogene laherparepvec对一名复发性局部晚期默克尔细胞癌患者产生完全临床缓解。
JAAD Case Rep. 2019 Sep 24;5(10):849-851. doi: 10.1016/j.jdcr.2019.07.006. eCollection 2019 Oct.
4
Talimogene laherparepvec in combination with pembrolizumab leads to a complete response in a patient with refractory Merkel cell carcinoma.瘤内注射人粒细胞-巨噬细胞集落刺激因子联合帕博利珠单抗治疗难治性默克尔细胞癌患者获完全缓解
JAAD Case Rep. 2018 Nov 7;4(10):1004-1006. doi: 10.1016/j.jdcr.2018.10.003. eCollection 2018 Nov.
5
Complete response of Merkel cell carcinoma with talimogene laherparepvec (TVEC) monotherapy. Merkel 细胞癌经替莫唑胺拉帕替尼单药治疗后完全缓解。
Dermatol Online J. 2022 Jan 15;28(1). doi: 10.5070/D328157059.
6
Complete remission from intralesional talimogene laherparepvec for regionally advanced Merkel cell carcinoma in an immunocompromised solid organ transplant patient.免疫功能低下的实体器官移植患者经病灶内注射talimogene laherparepvec后区域晚期默克尔细胞癌完全缓解。
JAAD Case Rep. 2021 May 26;13:144-146. doi: 10.1016/j.jdcr.2021.05.005. eCollection 2021 Jul.
7
Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma.替莫唑胺联合放疗治疗脑转移高级别胶质瘤的疗效及安全性分析
Australas J Dermatol. 2022 Aug;63(3):e222-e225. doi: 10.1111/ajd.13881. Epub 2022 Jun 6.
8
Administration and Handling of Talimogene Laherparepvec: An Intralesional Oncolytic Immunotherapy for Melanoma.塔利莫基因拉哈帕里韦克的给药与处理：一种用于黑色素瘤的瘤内溶瘤免疫疗法
Oncol Nurs Forum. 2016 Mar;43(2):219-26. doi: 10.1188/16.ONF.219-226.
9
A practical guide to the handling and administration of talimogene laherparepvec in Europe.欧洲塔利莫吉拉帕里韦克处理与给药实用指南
Onco Targets Ther. 2017 Aug 2;10:3867-3880. doi: 10.2147/OTT.S133699. eCollection 2017.
10
The safety of talimogene laherparepvec for the treatment of advanced melanoma.talimogene laherparepvec治疗晚期黑色素瘤的安全性。
Expert Opin Drug Saf. 2017 Feb;16(2):265-269. doi: 10.1080/14740338.2017.1274729. Epub 2016 Dec 28.

引用本文的文献

1
A Novel Intersection: Cytomegalovirus Gastritis Following Cemiplimab and Talimogene Laherparepvec in a Patient With Advanced Cutaneous Squamous Cell Carcinoma.一个新的交集：西米普利单抗和替利莫基因拉赫帕里韦克治疗晚期皮肤鳞状细胞癌患者后发生的巨细胞病毒性胃炎
Clin Case Rep. 2024 Dec 15;12(12):e9632. doi: 10.1002/ccr3.9632. eCollection 2024 Dec.
2
Systemic Therapy for Non-Melanoma Skin Cancers: Latest Advances.非黑色素瘤皮肤癌的系统治疗：最新进展。
Curr Oncol Rep. 2024 Sep;26(9):1120-1133. doi: 10.1007/s11912-024-01570-1. Epub 2024 Jul 2.
3
The Evolving Treatment Landscape of Merkel Cell Carcinoma.

本文引用的文献

1
Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of Melanoma.talimogene laherparepvec（T-VEC）及其他溶瘤病毒治疗黑色素瘤
Am J Clin Dermatol. 2017 Feb;18(1):1-15. doi: 10.1007/s40257-016-0238-9.
2
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.阿维鲁单抗治疗化疗难治性转移性默克尔细胞癌患者：一项多中心、单组、开放标签的2期试验。
Lancet Oncol. 2016 Oct;17(10):1374-1385. doi: 10.1016/S1470-2045(16)30364-3. Epub 2016 Sep 1.
3
Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma.
Merkel 细胞癌治疗领域的不断发展。
Curr Treat Options Oncol. 2023 Sep;24(9):1231-1258. doi: 10.1007/s11864-023-01118-8. Epub 2023 Jul 5.
4
Complete resolution of PD-1 refractory, locoregionally advanced Merkel cell carcinoma with talimogene laherparepvec.使用talimogene laherparepvec使PD-1难治性局部晚期默克尔细胞癌完全缓解。
JAAD Case Rep. 2023 Feb 6;36:15-17. doi: 10.1016/j.jdcr.2022.12.025. eCollection 2023 Jun.
5
Advances in Management and Therapeutics of Cutaneous Basal Cell Carcinoma.皮肤基底细胞癌的管理与治疗进展
Cancers (Basel). 2022 Jul 30;14(15):3720. doi: 10.3390/cancers14153720.
6
Talimogene Laherparepvec in Non-Melanoma Cancers.瘤内注射Talimogene Laherparepvec治疗非黑色素瘤癌症
J Clin Aesthet Dermatol. 2021 Nov;14(11):18-25.
7
How we treat Merkel cell carcinoma: within and beyond current guidelines.我们如何治疗 Merkel 细胞癌：现行指南内及以外的治疗方法。
Future Oncol. 2021 Apr;17(11):1363-1377. doi: 10.2217/fon-2020-1036. Epub 2021 Jan 29.
8
Current concepts and approaches to merkel cell carcinoma.默克尔细胞癌的当前概念和方法。
Arch Dermatol Res. 2021 Apr;313(3):129-138. doi: 10.1007/s00403-020-02107-9. Epub 2020 Jul 14.
9
Talimogene Laherparepvec in Advanced Mucosal Melanoma of the Urethra Upon Primary Resistance on Immune Checkpoint Inhibition: A Case Report.替利莫基因拉帕雷普韦克用于尿道原发性黏膜黑色素瘤在免疫检查点抑制治疗原发耐药后的应用：一例报告
Front Oncol. 2020 May 8;10:611. doi: 10.3389/fonc.2020.00611. eCollection 2020.
10
Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8 T Cells within Polyomavirus-Driven Merkel Cell Carcinomas.多瘤病毒驱动的 Merkel 细胞癌中普遍存在且多样化的肿瘤内癌蛋白特异性 CD8 T 细胞。
Cancer Immunol Res. 2020 May;8(5):648-659. doi: 10.1158/2326-6066.CIR-19-0647. Epub 2020 Mar 16.
替利莫吉尼联合伊匹单抗用于既往未治疗的不可切除ⅢB-Ⅳ期黑色素瘤
J Clin Oncol. 2016 Aug 1;34(22):2619-26. doi: 10.1200/JCO.2016.67.1529. Epub 2016 Jun 13.
4
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma.帕博利珠单抗用于晚期默克尔细胞癌的PD-1阻断治疗。
N Engl J Med. 2016 Jun 30;374(26):2542-52. doi: 10.1056/NEJMoa1603702. Epub 2016 Apr 19.
5
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study.从一项多机构的 II 期研究看，黑色素瘤患者接受替莫唑胺拉帕替尼治疗后的全身和局部反应。
J Immunother Cancer. 2016 Mar 15;4:12. doi: 10.1186/s40425-016-0116-2. eCollection 2016.
6
UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas.UV 相关突变是 MCV 阴性 Merkel 细胞癌发病机制的基础。
Cancer Res. 2015 Dec 15;75(24):5228-34. doi: 10.1158/0008-5472.CAN-15-1877. Epub 2015 Dec 1.
7
The Distinctive Mutational Spectra of Polyomavirus-Negative Merkel Cell Carcinoma.多瘤病毒阴性默克尔细胞癌的独特突变谱
Cancer Res. 2015 Sep 15;75(18):3720-3727. doi: 10.1158/0008-5472.CAN-15-0702. Epub 2015 Aug 3.
8
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.替莫唑胺胶丸联合放疗治疗恶性脑胶质瘤的疗效观察
J Clin Oncol. 2015 Sep 1;33(25):2780-8. doi: 10.1200/JCO.2014.58.3377. Epub 2015 May 26.
9
Merkel cell carcinoma: emerging biology, current approaches, and future directions.默克尔细胞癌：新兴生物学、当前治疗方法及未来方向
Am Soc Clin Oncol Educ Book. 2015:e519-26. doi: 10.14694/EdBook_AM.2015.35.e519.
10
Merkel cell carcinoma and Merkel cell polyomavirus: a systematic review and meta-analysis.默克尔细胞癌和默克尔细胞多瘤病毒：系统评价和荟萃分析。
Br J Dermatol. 2015 Jul;173(1):42-9. doi: 10.1111/bjd.13870. Epub 2015 Jun 12.